Wyeth Effexor "broken heart" ads cited by FDA; agency is concerned about post-MI antidepressant promos.
EFFEXOR AD LETTER REFLECTS FDA CONCERNS OVER POST-MI ANTIDEPRESSANT PROMOS, an issue that also figured in the warning letter FDA's Division of Drug Marketing, Advertising & Communication sent to Pfizer one year ago regarding Zoloft (sertraline). FDA sent a notice of violation letter to Wyeth-Ayerst July 25 concerning journal advertisements for the antidepressant Effexor (venlafaxine) that FDA maintained were "directed to depressed patient with concomitant heart disease."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth